Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
== Distribution == Aristotelia chilensis is native to Chile and Argentina near the southwest coast of South America. It is found naturally in Chilean rainforests. Its native range spans the area between the Coquimbo and Aysén regions of Chile, and is 170,000 hectares (420,000 acres) in total.
The Bain de Soleil brand transitioned from Procter & Gamble (P&G) to Pfizer in August 1995. The product recipes and certain pieces of manufacturing and packaging equipment were relocated from Hatboro, PA (P&G) to Pfizer Consumer Healthcare Group in Parsippany, New Jersey around October 1995. From November 1995 to 1999, the product was manufactured and packaged at the Pfizer CHCG 100 Jefferson Road, Parsippany, NJ site. During this time, the brand saw the largest portfolio enlargement, including self-tanning (sunless) and after-sun products. These products were all formulated at the same Pfizer site at the 400 Webro Road laboratories. Between 1995 and 1999, the following Bain de Soleil products were marketed:
Robert Byrd. The Senate, 1789–1989. Four volumes. Vol. I, a chronological series of addresses on the history of the Senate Vol. II, a topical series of addresses on various aspects of the Senate's operation and powers Vol. III, Classic Speeches, 1830–1993 Vol. IV, Historical Statistics, 1789–1992 Dole, Bob. Historical Almanac of the United States Senate Hatfield, Mark O., with the Senate Historical Office. Vice Presidents of the United States, 1789–1993 (essays reprinted online) Frumin, Alan S. Riddick's Senate Procedure. Washington, D.C.: Government Printing Office, 1992.
== Causes == Oxytocin deficiency is known to occur in conditions of hypopituitarism such as arginine vasopressin deficiency (central diabetes insipidus), craniopharyngiomas, and others. It may also occur in congenital diseases such as Prader–Willi syndrome and Schaaf–Yang syndrome. There has been interest in whether oxytocin deficiency may occur and cause symptoms in autism as well.
Sources: en.wikipedia.org
=== Names === Pizotifen is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while pizotyline is its USANTooltip United States Adopted Name. Brand names of pizotifen include Sandomigran, Mosegor, and Litec, among others.
== Further reading == Lampe, Markus, and Paul Sharp. A Land of Milk and Butter: How Elites Created the Modern Danish Dairy Industry (U of Chicago Press, 2018) online review Boberg-Fazlic, Nina; Jensen, Peter Sandholt; Lampe, Markus; Sharp, Paul; Skovsgaard, Christian Volmar (2023). "'Getting to Denmark': the role of agricultural elites for development". Journal of Economic Growth. 28 (4): 525–569. Kærgård, Niels (2023). "The Danish Economy, 1973–2009: From National Welfare State to International Market Economy". Scandinavian Journal of History
Partition chromatography is a specific form of column chromatography, specialized for separating analytes with only slight differences in partition coefficients between two liquid solvents. The solid phase in the chromatography column consists of particles coated with one liquid solvent, and the other liquid solvent acts as the eluent. Its theory and practice was introduced through the work and publications of Archer Martin and Richard Laurence Millington Synge during the 1940s. They would later receive the 1952 Nobel Prize in Chemistry "for their invention of partition chromatography".
Sources: en.wikipedia.org
=== Derivatives === Derivatives of nor-LSD substituted at the 6 position include LSD (METH-LAD; 6-methyl), ETH-LAD (6-ethyl), PRO-LAD (6-propyl), BU-LAD (6-butyl), AL-LAD (6-allyl), and PARGY-LAD (6-propynyl), among others. There appears to be a length of about 3 carbon atoms that can be tolerated at the 6 position before potent psychedelic activity is lost.
On December 31, 2019, due to safety concerns, Brady was transferred to the USP Big Sandy, a federal prison in Kentucky. In 2021, Brady was transferred to ADX Florence, a supermax federal prison in Colorado. As of 2025, Brady remains incarcerated at Florence.
== History == Beginning with William Harvey's experiments on the circulation of blood, recorded research into blood transfusion began in the 17th century, with successful experiments in transfusion between animals. However, successive attempts by physicians to transfuse animal blood into humans gave variable, often fatal, results.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.